In a groundbreaking advancement for cardiovascular science, researchers at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) in Spain, in collaboration with the Karolinska Institute in Sweden, have devised a cutting-edge technique to analyze the proteome of individual cardiomyocytes. These cells, essential for heart contraction, have long eluded comprehensive single-cell proteomic scrutiny due to technological limitations. This novel approach now allows for a detailed protein-level characterization of single heart muscle cells, opening unprecedented avenues for understanding heart biology and regeneration.

The heart has traditionally been viewed as an organ comprised of relatively homogeneous cardiomyocytes. However, recent findings highlight remarkable heterogeneity even within this single cell type. Variability in protein expression among cardiomyocytes may underpin differences in their functional capacity and regenerative potential. This study, published in Genome Biology, leverages an innovative integration of optimized cell isolation methods, advanced mass spectrometry, and sophisticated bioinformatic algorithms to dissect this proteomic diversity with extraordinary precision.

Central to their investigation was Myc, a transcription factor already noted for its role in regenerative strategies for heart repair. Despite its promise, until now the specific mechanisms by which Myc modulates protein expression in individual cardiomyocytes remained elusive. Applying their novel single-cell proteomics technology, the researchers uncovered that Myc expression differentially alters metabolic enzyme levels across single cardiomyocytes. This heterogeneity results in a subset of cells exhibiting distinct immature states, which in turn possess enhanced regenerative potential—a finding that transforms our comprehension of how cardiac regeneration might be selectively targeted.

The technical feat achieved by these scientists hinges on the fusion of multiple cutting-edge methodologies. First, the meticulous isolation of adult mouse cardiomyocytes ensures viable, intact cells reflecting true physiological states. These cells then undergo mass spectrometry procedures tailored for minute sample volumes, capable of identifying thousands of proteins with high sensitivity and quantitative accuracy at the single-cell level. The ensuing data are processed with bespoke computational pipelines designed to handle the intrinsic variability and noise characteristic of single-cell omics measurements.

By revealing the proteomic fingerprints that distinguish a pro-regenerative subpopulation of cardiomyocytes, this research elucidates a previously uncharted layer of cardiac cellular complexity. Understanding how Myc drives metabolic remodeling at the protein level provides a molecular explanation for its regenerative effects and establishes a foundation for engineering therapeutic approaches that harness or mimic these cellular states.

Regeneration in the adult mammalian heart remains a formidable challenge, owing largely to the low intrinsic capacity of cardiomyocytes to proliferate or replace damaged tissue after injury such as myocardial infarction. Previous models relying largely on bulk tissue analyses have masked the nuanced cellular dynamics at play. This single-cell approach offers resolution sufficient to detect rare but critical cell subsets that might hold the key to effective myocardial repair.

Moreover, this study underscores the transformative impact of integrating proteomics with single-cell biology, moving beyond transcriptomic analyses that often fail to predict functional protein abundance accurately. Proteins, as the primary effectors of cellular function, are the crucial link between gene regulation and phenotype. Hence, this proteomic lens provides a direct readout of the biochemical state of cardiomyocytes under regenerative cues.

The implications of this work extend beyond cardiac biology. It exemplifies the broader potential of single-cell proteomics to deepen our grasp of cellular heterogeneity in health and disease, from cancer biology to neurodegeneration. The refinement and dissemination of such methodologies will empower researchers across biomedical fields to uncover subtle but impactful cellular states previously hidden in ensemble measurements.

Miguel Torres and Jesús Vázquez, who co-led the CNIC teams responsible for this study, emphasize the critical novel insights gained. According to them, dissecting Myc’s action at the single-cell level illuminates pathways and protein networks that govern cellular immaturity and regeneration, which are masked in population-level studies. This knowledge fundamentally shifts how regenerative medicine strategies might be designed, focusing on targeted modulation of key proteins identified within pro-regenerative cardiomyocyte subgroups.

Consuelo Marín-Vicente, the study’s first author, highlights the heterogeneous response to Myc induction in adult cardiomyocytes. Instead of a uniform effect, Myc induces diverse proteomic profiles, driving some cells toward a state primed for regeneration. This discovery points to the existence of intrinsic regulatory mechanisms that govern cardiomyocyte plasticity, with possible manipulation routes to expand these favorable subpopulations therapeutically.

This advancement also signifies a leap toward personalized regenerative therapies. By characterizing the protein signatures specific to regenerative-competent cardiomyocytes, future interventions could selectively enhance these signatures in patient hearts, enabling more effective recovery post-injury. It also offers biomarkers to monitor therapeutic efficacy or to stratify patients likely to benefit from Myc-based or related regenerative treatments.

The CNIC, recognized as a Severo Ochoa Center of Excellence and funded by a unique public-private partnership, remains at the forefront of cardiovascular research. Under the leadership of Dr. Valentín Fuster, CNIC’s mission to translate scientific discoveries into clinical innovations is exemplified by this study’s promise. Collaboration with leading international centers like the Karolinska Institute further underscores the global effort to unravel heart regeneration’s complexity.

In sum, by pioneering a technique for single-cell proteomic analysis of adult cardiomyocytes, this research opens transformative possibilities for cardiovascular medicine. It elucidates how transcription factors like Myc can orchestrate heterogeneous proteomic landscapes within single cells, generating subpopulations equipped with regenerative capabilities. These insights herald a new era in designing precision therapies that could one day restore heart function after injury, dramatically improving outcomes for millions suffering from cardiovascular diseases worldwide.

---

Subject of Research: Cells

Article Title: Pro-regenerative fingerprints identified in a sub-population of adult mouse cardiomyocytes by integrative single-cell proteomics

News Publication Date: 22-May-2026

Web References:
10.1186/s13059-026-04110-1

Image Credits: CNIC

Keywords

Cardiomyocytes, Single-cell proteomics, Myc transcription factor, Heart regeneration, Mass spectrometry, Cellular heterogeneity, Cardiovascular disease, Protein expression, Regenerative medicine, Proteome, Metabolic enzymes, Cardiovascular research

Se você quer recomeçar do zero ou vendeu seu Pixel, veja como redefinir o Google Pixel Watch usando o telefone ou relógio.

Leia o restante do texto "Como redefinir o Google Pixel Watch usando o telefone ou relógio "

O post Como redefinir o Google Pixel Watch usando o telefone ou relógio apareceu primeiro em Blog do Edivaldo - Informações e Notícias sobre Linux.

Fin mai, le thermomètre a frôlé les 40 °C en France, confirmant l’urgence climatique après les étés étouffants de 2023 et 2025. Pour le secteur du BTP, la chaleur ne peut plus être gérée au coup par coup. Vinci, Bouygues, Eiffage… entre nouvelles obligations légales et retours d’expérience de...

No sooner has Starmer quit then media voices pipe up claiming he was a "good man". This, of course, is nonsense, says Nick Dixon. His two-tier, tin-eared response to the Southport murders showed he is anything but.

The post An Indecent Man appeared first on The Daily Sceptic.

Les Amazon Prime Days continuent de surprendre avec une offre incontournable pour votre confort intérieur ! Le Philips Purificateur d'air Série 8000 (AMF870/15), un appareil premium combinant trois fonctions indispensables, bénéficie d'un prix exceptionnel.

The interstellar comet 3I/ATLAS carries a chemical fingerprint unlike anything in our Solar System, and it may have formed 10 to 12 billion years ago, before our Sun even existed, according to two papers published in the journal Nature.

The post Interstellar Comet 3I/ATLAS Formed Up To 12 Billion Years Ago, New Observations Suggest appeared first on Sci.News: Breaking Science News.

Mavenir unveiled an Agentic Service Assurance Framework designed to automate complex network operations across multiple domains while allowing operators to retain existing infrastructure.

The vendor stated the TM Forum-compliant, multi-agent system combines an intent orchestrator with a layered agentic ecosystem to help detect, diagnose, recommend and resolve network faults faster.

Mavenir positioned the framework as a step toward higher operator productivity and autonomous network operations.

The vendor said network operations across 5G, cloud-native and IP domains are becoming increasingly fragmented and expensive to manage at scale. Traditional assurance systems can identify alarms but often struggle to determine root causes, while the retirement of experienced engineers risks taking years of institutional knowledge out of operations teams.

Multi-vendor environments add another layer of complexity by creating data silos which individual tools cannot easily correlate, according to Mavenir.

At the heart of the framework is Mavenir’s Intent Ops engine, which observes how network operations centre teams work, learns patterns behind successful issue resolution and converts those workflows into repeatable automation templates with explainability and guardrails.

The company explained the workflows are validated against a human baseline before running autonomously, with vetted automations published to an expanding orchestration catalogue.

The framework supports cross-domain monitoring, correlation and root-cause analysis, with closed-loop remediation built on Mavenir products.

It also connects with existing OSS AI agents through the agent-to-agent protocol defined in TM Forum’s IG1453, which Mavenir stated enables operators to preserve prior technology investments while extending automation across the network stack.

Mavenir CEO Pardeep Kohli told Mobile World Live the foundation AI agents are designed to automate 60% to 75% of routine network operations work, to help operators lower costs, improve service quality and reduce the need to train staff on repetitive tasks.

“In a way, you have a kind of personal assistant always watching you, but this personal assistant is for the network,” he said.

Mavenir did not say when it will be available but a representative stated the initial release is being trialled in customer deployments and future feature releases will be delivered through software upgrades.

The post Mavenir debuts agentic automation framework appeared first on Mobile World Live.

HD 80606b has one of the most extreme orbits of any known exoplanet and the NASA/ESA/CSA James Webb Space Telescope just caught it getting flash-fried as it whipped past its star.

The post Webb Sees Jupiter-Size Exoplanet Being Roasted by Its Star appeared first on Sci.News: Breaking Science News.

Été 1925. Un professeur convaincu que dormir est une perte de temps lance un défi radical à sept étudiants : les tenir éveillés pendant 60 heures d'affilée. Une expérience folle, menée à Washington dans un contexte d'euphorie industrielle. Et si cette nuit blanche prolongée avait finalement...

Le 28 mai dernier, Yaëlle Wormser remporte le premier prix du jury de la finale nationale du concours Ma Thèse en 180 secondes. Sciences et Avenir est allé à la rencontre de cette doctorante de l’Institut Pasteur au parcours unique.

Mavenir and Red Hat announced what they are calling an Integrated AI Platform, a joint offering designed to give mobile operators the infrastructure to sell services and capture revenue currently flowing to hyperscalers and frontier AI companies.

After making the decision to pivot away from open RAN last year, the vendor has turned its focus to AI, which is evidenced in its partnership with Red Hat.

The Integrated AI Platform blends Mavenir’s AI software with Red Hat’s enterprise Kubernetes and AI capabilities using the latter’s OpenShift and the former’s Digital Enablement (MDE) platform for billing and charging.

The result is a platform which enables operators to monetise AI through token-based consumption plans, with full control over pricing, SLAs and the large language models (LLMs) which power every interaction.

The two companies believe token-based AI consumption, the unit model powering every LLM interaction, mirrors the mobile data billing paradigm operators have long used.

Mobile operators spent decades mastering consumption-based data billing, and Mavenir CEO Pardeep Kohli believes the same model can now be applied to AI while also capturing AI revenue currently flowing to the likes of OpenAI, Anthropic and the major hyperscalers.

 “At the end of the day, most of the money is going to go to OpenAI and all these other players,” Kohli told Mobile World Live. “What we are hoping is that this time, there’s an opportunity for operators not only to use AI to cut their own cost and reduce opex and do more automation but also be a provider of AI services to enterprises or even to consumers.”

How it works
The AI platform operates across three deployment models: operator-branded AI services for their own subscribers; as the AI infrastructure layer powering operator AI grid deployments; and as a managed AI platform through which operators can offer the capabilities to enterprise customers on a consumption basis.

The architecture is designed as hybrid, using on-premises and open-source models to serve most of the traffic, while Mavenir’s model router provides policy-governed, metered access to external frontier models for use cases which require advanced reasoning or multimodal capability.

Kohli explained every generation of mobile technology, from 3G to 5G, saw the bulk of value flow to application developers and hyperscalers while operators became commoditised connectivity pipes.

He believes AI represents a rare chance to break that cycle, provided operators move fast enough to control the infrastructure layer. Kohli pointed to live deployments, including Turkcell running on-premises language models and Telefonica working with Mavenir on a range of use cases announced at MWC, as evidence the strategy is already in motion rather than theoretical.

Use cases
One example he provided MWL is real-time voice translation. An operator customer of Mavenir is deploying an agent which converts live calls between languages.

At a small scale, routing the workload through a hyperscaler is economically viable. At the scale of a major mobile network, it becomes prohibitively expensive unless the inference runs on infrastructure the operator controls directly.

The AI platform, as Kohli describes it, is the mechanism which makes the transition possible without rebuilding the operator’s entire operational model.

Kohli also said currently when a mobile operator customer sends a query to Gemini or OpenAI, it bypasses the operator entirely and then goes straight to the hyperscaler’s data centre with the operator earning nothing beyond the data connection.

His AI grid model changes the scenario by making the operator an intelligent routing layer. A simple query gets handled by a local on-premises model at low cost; a complex reasoning task gets routed to a frontier model; a non-urgent request could be sent to a cheaper, more distant data centre.

With the AI grid, the operator becomes a traffic controller in the AI value chain rather than, as Kohli put it, “a dump pipe”.

Sovereign angle
Regulated operators in markets with strict data residency requirements have ample reasons to prefer on-premises inference over sending subscriber data to hyperscaler data centres in unspecified jurisdictions.

The physical proximity argument of operators has merit as Kohli noted operators with urban data centres genuinely are better placed than hyperscalers whose capacity often sits in rural locations.

“We are going use case by use case, but the actual framework and platform is common, and it can be used for many applications,” he said.

Analyst outlook
AvidThink founder and principal Roy Chua raises several issues with the token-as-currency model. One of his points is a token is not a megabyte. A megabyte is a fixed, fungible unit of information.

He explained a token from a frontier reasoning model and a token from a fine-tuned small language model running on premises are not equivalent. One may resolve a complex problem immediately while the other “takes 10 times the tokens getting to a worse answer”.

Chua said the intelligence embedded in a token varies wildly between models, and tokenisation methods differ between model families. Until there is an established, auditable standard for what a token represents in terms of capability, he argues, “the token can’t function as the billing primitive”.

There is also the question of where developer loyalty sits today. Enterprises and software developers have built their AI workflows around the frontier labs and around aggregation layers which already solve model routing across providers.

“For developers and enterprises, trying to insert the operator into a value chain where most operators currently have no relationships and add little differentiated value is an uphill climb,” he said.

He stated a stronger move is not selling tokens as a currency, but selling sovereign, compliant, latency-advantaged AI services wrapped in outcomes, particularly for regulated buyers who need in-country control.

“Let me give credit where it’s due,” Chua said. “Pardeep Kohli and the Mavenir team have correctly identified the macro tailwind. The geopolitics around AI access are real, data sovereignty pressures are real, and the desire for operators to climb the value stack is older than the cloud itself.”

He continued: “However, token-as-a-service, isn’t a sellable product yet for most telcos, with very few exceptions. Someone like SoftBank could do it in the future.”

DTW Ignite
Kohli said Mavenir will have a booth for the first time at TM Forum’s DTW Ignite conference next week. Historically, he noted, DTW was the domain of operators’ IT and billing-side teams while Mobile World Congress served the network side.

Mavenir’s presence at DTW now reflects his view those two worlds are converging as operators build common platforms spanning both functions.

 “We have a booth now to explain how we can actually have a common platform, which can not only do billing and charging, customer onboarding and customer facing work, but also can manage your network,” he said. “And it learns about packet code, and it learns about voice calling, it learns about SMS, MMS and not just your bill.

“I believe this is a golden opportunity,” he added.

The post Analysis: Mavenir pitches AI tokens as a telco cash cow appeared first on Mobile World Live.

Everyone knows that Tony Blair and the Pope issued encyclicals in the last week or two. The Pope's was entitled ‘Magnifica Humanitas’; by analogy, Blair's should have been called ‘Labor Imbecilis’, says James Alexander.

The post Blair’s Encyclical Labor Imbecilis appeared first on The Daily Sceptic.

Good phone repair companies tend to be serious about delivering dependable service, careful craftsmanship, and a steady repair

In a groundbreaking advance poised to transform the landscape of age-related immune decline, University College London (UCL) researchers are spearheading a pioneering clinical trial aimed at rejuvenating worn-out T cells through an innovative immune restoration therapy. This Phase 1 first-in-human study will explore the therapeutic potential of metabolically resetting exhausted or senescent T cells, a subset of immune cells that accumulate with age and chronic disease and lose their robustness in coordinating immune responses. The initiative promises to reopen avenues for combating a spectrum of diseases, including cancer, HIV, and neurodegenerative disorders like dementia, by profoundly modifying the immune system’s intrinsic capacity to defend and repair.

Central to the research is the recognition that immune ageing, characterized by the progressive dysfunction and decline in immune cell performance, is a key factor leading to increased vulnerability in the elderly and those with chronic infections. T cells, particularly the CD4+ subtype—often regarded as the conductors of the immune orchestra—become less effective with time, diminishing the immune system’s ability to coordinate defenses accurately. These cells, rendered senescent or exhausted, exhibit impaired proliferation, cytokine production, and cytotoxic activity, undermining responses to pathogens, malignancies, and cellular damage.

The novel therapy, developed by SenTcell, a biotech startup founded by Dr. Alessio Lanna from UCL Medicine, employs a liquid formulation administered intramuscularly akin to conventional vaccines. This delivery method facilitates patient-friendly administration while targeting key metabolic pathways within dysfunctional T cells. By reprogramming the intracellular environment of these immune cells, the treatment aims to restore youthful functional properties, including enhanced proliferative capacity and efficient pathogen recognition, thereby revitalizing the immune system’s broad protective functions.

Dr. Lanna explains that although antiretroviral advancements have significantly improved lifespans for individuals living with HIV, many still experience premature immune ageing. Similar patterns of immune exhaustion are also detected in cancer patients and other chronic disease cohorts. The imminent clinical trial represents a critical stepping stone towards verifying whether exhausted immune cells can be safely and effectively rejuvenated in human subjects, with the potential to redefine therapeutic paradigms for diseases rooted in immune dysregulation.

At the molecular level, one of the intriguing aspects under investigation involves the role of telomeres—protective caps on chromosome ends whose shortening serves as a hallmark of biological ageing. Laboratory studies have suggested that rejuvenated CD4+ T cells may release telomere-containing extracellular structures, whimsically termed “telomere Rivers,” into the bloodstream. The presence and behavior of these structures might offer novel insights into how restored immune cells influence systemic health, extending their benefits beyond immediate immune niches to broader tissue health. Although this phenomenon has yet to be validated in human clinical contexts, it highlights the sophisticated interplay between immune rejuvenation and organismal aging.

The clinical trial enjoys regulatory support from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) through its Innovative Licensing and Access Pathway (ILAP), underscoring the therapy’s potential to meet the pressing unmet medical needs associated with immune senescence. This endorsement accelerates development timelines and affirms the significance of targeting immune metabolic dysfunction as a viable therapeutic strategy.

Participants in the upcoming Phase 1 trial will be meticulously selected adults exhibiting characteristics of immune dysfunction, including evidence of premature immune ageing or persistent viral infections. Comprehensive immune profiling will be conducted before and after therapeutic administration to discern immunological changes and safety outcomes. Although the initial focus is on evaluating biological activity and tolerability, successful results could pave the way for advanced trials assessing clinical efficacy.

Unlike conventional treatments that combat diseases by targeting individual pathogens or tumor cells directly, this therapy seeks to recalibrate the immune system itself—restoring its intrinsic resilience and regenerative functionality. Such a paradigm shift holds profound implications; by enhancing the immune system’s natural defensive repertoire, it may afford broad-spectrum protection and facilitate healthier ageing trajectories.

Beyond chronic infections like HIV and cancer, this approach could ultimately apply to autoimmune disorders characterized by immune exhaustion, wherein overly active yet dysfunctional immune cells drive pathology. Immune rejuvenation strategies offer a novel means of restoring balance without broadly suppressing immune activity, potentially mitigating disease progression while improving quality of life.

This research aligns with a growing global focus on understanding the cellular and molecular underpinnings of ageing and immune decline. By intervening at the level of T cell metabolism and function, scientists hope to extend not only lifespan but healthspan—preserving cognitive and physical function while reducing susceptibility to infections, cancer, and degenerative diseases.

As UCL celebrates two centuries of academic excellence and innovation, this project embodies the institution’s commitment to translating bold scientific ideas into therapies capable of reshaping medicine. If validated through clinical trials, this immune rejuvenation therapy could herald a transformative era in treating age-associated diseases, offering hope for millions affected by immune dysfunction worldwide.

Subject of Research: People
Article Title: Immune Rejuvenation: UCL’s Pioneering Trial Targets T Cell Exhaustion to Combat Age-Related Immune Decline
News Publication Date: Not provided
Web References: www.ucl.ac.uk
References: Not provided
Image Credits: Not provided
Keywords: Immune ageing, T cell exhaustion, CD4+ T cells, immune rejuvenation, senescent immune cells, telomeres, immune dysfunction, chronic disease, HIV, cancer, metabolic resetting, Phase 1 clinical trial

La DGSI rompt avec son prestataire américain historique Palantir, 10 ans après les attentats du 13-novembre. Un virage stratégique qui fait également école outre-Rhin. Futura fait le point sur l'inquiétant géant américain Palantir et son remplaçant, le français ChapsVision encore inconnu du...

La pollution atmosphérique est un fardeau de plus en plus lourd. La dernière étude de Santé publique France pointe les nombreuses maladies chroniques, respiratoires, cardiovasculaires et métaboliques qu'elle provoque, touchant particulièrement les enfants et les personnes vulnérables. Chaque...

A groundbreaking discovery at the University of California, Los Angeles (UCLA) has unveiled a promising new therapeutic avenue for kidney regeneration, leveraging a drug initially designed to repair heart tissue following myocardial infarction. This drug, known as AD-NP1, targets a specific protein—ENPP1—that plays a critical role in impeding the body’s natural healing processes in injured tissues. The revelation that AD-NP1 can also accelerate kidney repair heralds a significant advancement in regenerative medicine, especially for patients suffering from chronic kidney disease (CKD), a condition that affects millions globally.

The heart of this research revolves around a protein named ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). When tissues such as the heart or kidney sustain injury, ENPP1 production escalates, initiating a cascade of metabolic disturbances that hinder energy synthesis within cells. This disruption compromises cellular function and ultimately stalls effective tissue regeneration. In the context of the kidney, which is vital for maintaining systemic homeostasis, such impediments can lead to progressive scarring and functional decline, culminating in kidney failure.

Through years of meticulous experiments, the UCLA team delineated the detrimental impact of ENPP1 on the kidney’s reparative capacity. They observed that injured renal tissue upregulates ENPP1 expression, which in turn resets the metabolic landscape of cells in the damaged microenvironment. This altered metabolic signaling disrupts mitochondrial function, thereby curtailing ATP production essential for cell proliferation and repair. By employing genetic knockout models in mice, where ENPP1 expression was inhibited, the researchers documented a striking enhancement in renal recovery post-injury. These mice demonstrated reduced fibrotic scarring and improved renal biomarkers, signaling restored kidney function.

Central to translating these findings into potential clinical interventions is AD-NP1, a sophisticated monoclonal antibody engineered to specifically neutralize ENPP1. Unlike broad-spectrum immunosuppressants or anti-inflammatory agents, AD-NP1 offers targeted therapeutic precision by binding solely to human ENPP1, circumventing off-target effects. Initially conceptualized to mitigate cardiac fibrosis and promote myocardial regeneration following heart attacks, AD-NP1’s mechanism exerts a similar rejuvenating influence on kidney tissues. The antibody effectively halts the ENPP1-induced metabolic sabotage, facilitating an environment conducive to cellular proliferation and tissue repair.

In experimental paradigms, the administration of AD-NP1 in mice subjected to nephrotoxic diets and chemically induced renal injuries yielded compelling outcomes. Within merely seven days of treatment, subjects exhibited marked improvements in kidney function tests and histological assessments showed diminished collagen deposition and scarring. These findings underscore the drug’s potential to transform the management of acute and chronic kidney injuries by reinstating the organ’s intrinsic regenerative programs, which are often stifled in disease states.

Moreover, the team’s translational approach integrated analyses of human kidney biopsies acquired from individuals with chronic kidney disease. These samples consistently manifested elevated ENPP1 levels relative to healthy controls, substantiating the protein’s pathological role in human renal disorders. This correlation not only reinforces the relevance of the preclinical models used but also paves the way for clinical evaluation of AD-NP1’s efficacy in human subjects suffering from renal ailments.

The broader implications of this discovery extend into the metabolic regulation of tissue repair. ENPP1’s role appears multifaceted, orchestrating cellular energy dynamics and intercellular communication networks that dictate regenerative outcomes. Inhibiting this protein intervenes in maladaptive signaling cascades, thereby restoring bioenergetic balance and enabling clonal expansion of healthy cells adjacent to injury sites. This paradigm shift in understanding organ regeneration emphasizes metabolic modulation as a cornerstone of effective healing strategies.

Prior to this research, the therapeutic targeting of ENPP1 was primarily confined to cardiac medicine. The successful repurposing of AD-NP1 for kidney injury illustrates the concept of cross-organ regenerative mechanisms, where molecular pathways governing tissue healing are conserved albeit contextually modulated. This discovery propels the field into a new frontier, advocating for the exploration of shared regenerative targets that can be manipulated across diverse organ systems.

AD-NP1’s journey into clinical trials commenced recently with FDA approval of a Phase 1 safety study in human patients recovering from heart attacks. This milestone reflects the rigorous preclinical validation of the drug’s pharmacodynamics and safety profile. Building on these milestones, ongoing efforts at UCLA aim to extend these trials to include patients with progressive kidney disease, setting the stage for comprehensive evaluation and potential future clinical application.

Underlying this innovative research are substantial investments from the National Institutes of Health, California Institute of Regenerative Medicine, and the U.S. Department of Defense. This underscores the strategic importance and translational potential of regenerative medicine therapies in addressing chronic diseases that impose heavy societal burdens. The interdisciplinary collaboration among cardiovascular scientists, nephrologists, and molecular biologists at UCLA exemplifies the synergy needed to unlock complex biological processes for therapeutic gain.

In summation, the identification of ENPP1 as a metabolic gatekeeper that impedes tissue repair, combined with the development of AD-NP1 to neutralize its effects, represents a significant leap forward in regenerative medicine. The drug’s ability to foster organ regeneration by restoring metabolic and cellular homeostasis offers hope for millions afflicted by kidney disease and opens novel avenues for organ repair strategies. As clinical trials progress, the scientific community eagerly anticipates further validation of these findings, potentially heralding a new era where molecularly targeted therapies can substantially reverse organ damage and restore quality of life.

Subject of Research: Kidney regeneration, metabolic regulation of tissue repair, ENPP1 protein inhibition, monoclonal antibody therapy

Article Title: UCLA Researchers Discover Novel Role for ENPP1 Inhibition in Enhancing Kidney Repair via AD-NP1

News Publication Date: Not specified (based on provided content)

Web References: Cell Stem Cell Journal Article

Keywords: ENPP1, kidney injury, chronic kidney disease, tissue regeneration, monoclonal antibody, AD-NP1, metabolic signaling, renal repair, fibrosis, UCLA, regenerative medicine, Phase 1 clinical trial

En cherchant à remonter toujours plus loin dans le temps pour observer les développements précoces des quasars, ces prodigieux phares cosmiques, les astrophysiciens tentent de reconstituer les conditions qui ont permis la formation des premiers trous noirs supermassifs, lesquels ont influencé...

The release of macOS 27 later this fall won't quite close the book on the Intel Mac. The last handful of models that could run macOS 26 Tahoe will be eligible for security and Safari updates for two more years, and elements of the Rosetta compatibility layer for running Intel code on Apple Silicon Macs will be with us in some form for some indeterminate amount of time after that.

But macOS 26 is definitely the last chapter of the Intel Mac story. Anything that happens after this is a coda or an epilogue.

Most of our WWDC coverage has been forward-looking, so indulge us if you will in a look backward at the full history of the Intel Mac, a partnership between two companies that made Macs dramatically better, until it started making them worse.

Read full article

Comments

© David Paul Morris/Getty Images

Nuits courtes en perspective... La Coupe du monde de football 2026 va contraindre de nombreux supporters européens à veiller tard pour suivre les matchs en direct. En raison du décalage horaire avec les États-Unis, le Canada et le Mexique, pays hôtes de la compétition, plusieurs rencontres...